Product Overview
Dragon Pharma CY3 is a single oral tablet that carries three different fat-loss agents at fixed strengths: 37 mcg of clenbuterol, 25 mcg of liothyronine sodium (T3) and 5.4 mg of yohimbine, in packs of 100 tablets. They sit together in one tablet because each closes a different route to the same result and none of them reproduces the others: clenbuterol is a beta-2 adrenergic agonist that drives lipolysis and heat production, T3 is the active thyroid hormone that sets basal metabolic rate, and yohimbine blocks the alpha-2 receptor that normally brakes fat release from storage. Because the strengths are fixed, so is the ratio, and the only lever is how many tablets are taken - the three are one formula, not three products dosed side by side.
Nothing in the tablet is a steroid. There is no aromatization, no estrogenic water retention and no 17-alpha-alkylation, so the hepatic profile is unremarkable. The pharmacokinetics are also very uneven: clenbuterol is quoted at 36-48 hours by reference material, about 35 hours in one 2025 review and 25-39 hours in the enforcement literature; T3 runs at roughly two and a half days; yohimbine clears in 0.25-2.5 hours. Practical behaviour therefore follows the slow end of the formula, and one morning dose a day holds a steady level, which is why the separate Clenbuterol and T3 cards are the wrong place to add more of the same.
The main hazard is the combination itself. Published material on liothyronine records particularly serious toxicity when a thyroid hormone is taken together with a sympathomimetic, and clenbuterol is exactly that; clenbuterol also carries documented cardiac events at high doses. An injectable format of the same two ideas exists as Helios, and it is not a partner for CY3 for the same reason. This product is for a short, monitored diet phase by someone who understands the monitoring, not for a beginner and not for anyone with a cardiac history.
Dosage Protocol
The tablet strength fixes the ratio, so the only lever is how many tablets are taken. No published protocol for the finished blend exists, so the table works from the clenbuterol and T3 figures below and stays inside the range sources treat as tolerable.
| Beginner | Half a tablet a day, short block - equal to 18.5 mcg clenbuterol, 12.5 mcg T3 and 2.7 mg yohimbine; no specific protocol for the blend is documented |
| Intermediate | 1 tablet a day, short block - 37 mcg of clenbuterol sits below the 60-120 mcg range sources describe for sport use |
| Advanced | 2 tablets a day, short block - 74 mcg clenbuterol with 50 mcg T3; beyond roughly 120 mcg of clenbuterol, tremor, headache and dizziness are documented |
| Female | Half a tablet a day, short block - no verified female protocol exists in the sources consulted |
| Administration | Oral, once a day - single dose in the first half of the day, because clenbuterol clears slowly; never alongside another stimulant or standalone T3 |
Suggested Protocols
CY3 is a short block, not a base, so every route below pairs it with something else and then ends it. The products named open their own pages in the same brand section.
What to Expect
- Raised temperature and pulse. Within a day or two, with a light tremor from the clenbuterol; this is the expected onset, not a warning that something went wrong.
- More sweating and faster fat loss. Across the first week, with early scale movement that mixes water and fat.
- Peak effect. Usually week two to three, while the yohimbine contribution fades within hours of each tablet and the clenbuterol and T3 levels stay flat.
- Receptor adaptation. By week three or four the same dose does less and the side effects do more, which is the point to stop.
- Combination toxicity. A thyroid hormone taken with a sympathomimetic is described as particularly serious, so the two are never separated in this tablet.
- Thyroid suppression. T3 suppresses the body's own thyroid output, so the block is not ended without TSH, T3 and T4 results.
- Slow fade after stopping. With T3 at about two and a half days and clenbuterol at 36-48 hours, symptoms linger for days and thyroid function is retested weeks later.
Side Effects and Management
The side effects of this blend are carried by the heart, the thyroid and the nervous system, and almost all of them are dose-dependent.
Recovery and Thyroid Follow-Up
There is no HPTA axis to restart here because no component is a steroid, so recovery means pulling the thyroid and the beta-2 receptors back to baseline instead.
